Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 22/11/2020
SIETES contiene 93161 citas

 
 
 1 a 20 de 176 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Hill K, Sucha E, Rhodes E, Carrier M, Garg AX, Harel Z, Hundemer GL, Clark EG, Knoll G, McArthur E, Sood MM. Risk of hospitalization with hemorrhage among older adults taking clarithromycin vs azithromycin and direct oral anticoagulants. JAMA Intern Med 2020:8 de junio. [Ref.ID 103655]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Dal-Ré R, Kesselheim AS, Bourgeois FT. Increasing access to FDA inspection reports on irregularities and misconduct in clinical trials. JAMA 2020:23 de abril. [Ref.ID 103599]
4.Enlace a cita original Cita con resumen
Lutsey PL, Norby FL, Ensrud KE, MacLehose RF, Diem SJ, Chen LY, Alonso A. Association of anticoagulant therapy with risk of fracture among patients with atrial fibrillation. JAMA Intern Med 2019:25 de noviembre. [Ref.ID 103220]
5.Enlace a cita original Cita con resumen
Garmendia CA, Gorra LN, Rodríguez AL, Trepka MJ, Veledar E, Madhivanan P. Evaluation of the inclusion of studies identified by the FDA as having falsified data in the results of meta-analyses. The example of the apixaban trials. JAMA Intern Med 2019;179:4 de marzo. [Ref.ID 103094]
7.Enlace a cita original Cita con resumen
Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, Stein M. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA 2018;320:4 de diciembre. [Ref.ID 102867]
8.Enlace a cita original Cita con resumen
Moore TJ, Hanzhe Z, Anderson G, Alexander C. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016. JAMA Intern Med 2018:24 de septiembre. [Ref.ID 102831]
9.Enlace a cita original Cita con resumen
Huang W-Y, Singer DE, Wu J-L, Chiang C-E, Weng H-H, Lee M, Ovbiagele B. Association of intracranial hemorrhage risk with non–vitamin K antagonist oral anticoagulant use vs aspirin use. A systematic review and meta-analysis. JAMA Neurology 2018:13 de agosto. [Ref.ID 102795]
10.Enlace a cita original Cita con resumen
Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ 2018;361:4 de julio. [Ref.ID 102751]
11. Cita con resumen
Anónimo. Edoxaban: Interstitial lung disease. Japan . WHO Drug Information 2018;32:18. [Ref.ID 102620]
12.Enlace a cita original Cita con resumen
Hart RG, Sharma M, Mundl H, Kasner SE, Bagdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Davalos A, Shamalov N, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonskowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, Endres M, Muir KW, Bornstein N, Ozturk S, O'Donnell MJ, De Vries Basson MM, Pare G, Pater C, Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A, Benavente OR, Joyner C, Themeles E, Connolly SJ, NAVIGATE ESUS Investigators. Ribaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018;378:2191-201. [Ref.ID 102610]
13.Enlace a cita originalTiene citas relacionadas Cita con resumen
Dekkers T, Lafeber M, Kramers C. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102523]
14.Enlace a cita originalTiene citas relacionadas Cita con resumen
Wang X, Karnieg T. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102522]
15.Enlace a cita original Cita con resumen
Uyhazi KE, Miano T, Pan W, VanderBeek BL. Association of novel oral antithrombotics with the risk of intraocular bleeding. Jama Ophthalmol 2017:14 de diciembre. [Ref.ID 102190]
17. Cita con resumen
López-López JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, Davies PA, Bodalia PN, Bryden PA, Welton NJ, Hollingworth W, Caldwell DM, Savovic J, Dias S, Salisbury C, Eaton D, Stephens-Boal A, Sofat R. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 2017;359:j5058. [Ref.ID 102157]
18. Cita con resumen
Maura G, Pariente A, Alla F, Billionnet C. Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a french nationwide cohort study. Pharmacoepidemiol Drug Saf 2017;26:1367-77. [Ref.ID 102133]
19. Cita con resumen
Kjerpeseth LJ, Ellekjær H, Selmer R, Ariansen I, Furu K, Skovlund E. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. Eur J Clin Pharmacol 2017;73:1417-25. [Ref.ID 102130]
20. Cita con resumen
Fanning L, Ilomäki J, Bell JS, Darzinš P. The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation. Eur J Clin Pharmacol 2017;73:1427-36. [Ref.ID 102129]
Seleccionar todas
 
 1 a 20 de 176 siguiente >>